Home › Funds › ORBIMED ADVISORS LLC › KRYS

ORBIMED ADVISORS LLC position in KRYS

KRYSTAL BIOTECH INC · Health Care

ORBIMED ADVISORS LLC reported holding 83,200 shares of KRYS (KRYSTAL BIOTECH INC) in its Q2 2026 13F filing — a position valued at US$30.9M, representing 0.62% of its reported portfolio and ranking #43 among its reported holdings. ORBIMED ADVISORS LLC has disclosed KRYS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)83.20K sh
Reported value held$30.92M
Portfolio Weight0.62%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's KRYS position evolved

ORBIMED ADVISORS LLC first disclosed a stake in KRYS in Q4 2023 at 103,700 shares (US$12.9M). The position peaked in Q2 2026 at 83,200 shares, worth US$30.9M. Across 11 filings, ORBIMED ADVISORS LLC increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 83,200 shares valued at US$30.9M — an increase of 14,100 shares quarter over quarter.. Notable position changes include a 64% trim in Q1 2024 (shares rose 3% over the following quarter), a 61% trim in Q2 2025 (shares rose 28% over the following quarter), a 1017% increase in Q3 2025 (shares rose 40% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 103.70K $12.87M New
Q1 2024 37.17K $6.61M Reduce
Q2 2024 29.97K $5.50M Reduce
Q3 2024 23.50K $4.28M Reduce
Q4 2024 23.50K $3.68M Hold
Q1 2025 23.50K $4.24M Hold
Q2 2025 9.20K $1.26M Reduce
Q3 2025 102.75K $18.14M Add
Q4 2025 119.80K $29.54M Add
Q1 2026 69.10K $17.85M Reduce
Q2 2026 83.20K $30.92M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KRYS and 13F data

KRYS (KRYSTAL BIOTECH INC) is a Health Care company. 49 other funds we track also report a position in KRYS — the largest reported positions include Avoro Capital Advisors LLC (US$1.07B), Soleus Capital Management, L.P. (US$349.1M), Hood River Capital Management LLC (US$246.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KRYS

All KRYS fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held KRYS?

ORBIMED ADVISORS LLC has disclosed KRYS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is ORBIMED ADVISORS LLC's current position in KRYS?

As of Q2 2026, ORBIMED ADVISORS LLC holds 83.20K shares of KRYS (KRYSTAL BIOTECH INC), valued at $30.92M, representing 0.62% of its reported portfolio and ranking #43.

Has ORBIMED ADVISORS LLC been buying or selling KRYS?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in KRYS. The position peaked in Q2 2026 at 83.20K shares.

Which other funds hold KRYS?

Other major institutional holders of KRYS include Avoro Capital Advisors LLC, Soleus Capital Management, L.P., Hood River Capital Management LLC, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.